Literature DB >> 21454871

The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply).

Giuseppe Visani, Massimo Breccia, Enrico Montefusco, Enrica Morra, Valeria Santini, Alessandro Isidori.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21454871      PMCID： PMC3069247          DOI： 10.3324/haematol.2011.041319

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  6 in total

1.  Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients.

Authors:  Giuseppe Visani; Massimo Breccia; Antonella Gozzini; Giorgina Specchia; Enrico Montefusco; Enrica Morra; Mario Annunziata; Andrea Camera; Francesco Cavazzini; Fabio Stagno; Patrizia Pregno; Emilio Usala; Valeria Santini; Pier Paolo Piccaluga; Alessandro Isidori
Journal:  Am J Hematol       Date:  2010-12       Impact factor: 10.047

Review 2.  Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.

Authors:  Massimo Breccia; Giuliana Alimena
Journal:  Expert Opin Drug Saf       Date:  2010-09       Impact factor: 4.250

3.  Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis.

Authors:  Hugues de Lavallade; Sinthiya Punnialingam; Dragana Milojkovic; Marco Bua; Jamshid S Khorashad; Ian H Gabriel; Aristeidis Chaidos; Eduardo Olavarria; John M Goldman; Jane F Apperley; David Marin
Journal:  Br J Haematol       Date:  2008-03-07       Impact factor: 6.998

4.  Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily.

Authors:  Maria-Theresa Krauth; Susanne Herndlhofer; Maria-Theresa Schmook; Gerlinde Mitterbauer-Hohendanner; Ernst Schlögl; Peter Valent
Journal:  Haematologica       Date:  2010-10-07       Impact factor: 9.941

5.  Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Susan O'brien; Gautham Borthakur; John Bruzzi; Reginald Munden; Jorge Cortes
Journal:  J Clin Oncol       Date:  2007-09-01       Impact factor: 44.544

6.  Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion.

Authors:  Kimmo Porkka; H Jean Khoury; Ronald L Paquette; Yousif Matloub; Ritwik Sinha; Jorge E Cortes
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860
  6 in total
  1 in total

Review 1.  Cardiotoxicity of Novel Targeted Hematological Therapies.

Authors:  Valentina Giudice; Carmine Vecchione; Carmine Selleri
Journal:  Life (Basel)       Date:  2020-12-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.